Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MMP2 | P08253 | 5/20 | 0.34 |
| ▸ | MMP9 | P14780 | 5/20 | 0.34 |
| ▸ | MMP8 | P22894 | 4/20 | 0.34 |
| ▸ | MMP12 | P39900 | 4/20 | 0.34 |
| ▸ | MMP14 | P50281 | 4/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | CCKAR | P32238 | 1/20 | 0.33 |
| ▸ | CCKBR | P32239 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17424474 | 0.91 | GLP1R (0.53) | GLP1RALDH1A1MMP2MMP9MMP8 | |
| SCHEMBL25454221 | 0.90 | GLP1R (0.51) | GLP1RALDH1A1MMP2MMP9MMP8 | |
| SCHEMBL14240744 | 0.89 | GLP1R (0.50) | GLP1RALDH1A1MMP2MMP9MMP8 | |
| SCHEMBL27120318 | 0.89 | GLP1R (0.50) | GLP1RALDH1A1MMP2MMP9MMP8 | |
| SCHEMBL27119968 | 0.89 | GLP1R (0.50) | GLP1RALDH1A1MEN1KMT2A | |
| SCHEMBL27120257 | 0.89 | GLP1R (0.50) | GLP1RALDH1A1MEN1KMT2A | |
| SCHEMBL21440827 | 0.89 | GLP1R (0.50) | GLP1RALDH1A1MMP2MMP9MMP8 | |
| SCHEMBL71086 | 0.89 | GLP1R (0.50) | GLP1RALDH1A1MMP2MMP9MMP8 | |
| SCHEMBL14685783 | 0.88 | GLP1R (0.54) | GLP1RMEN1KMT2ARECQL | |
| SCHEMBL21096839 | 0.88 | GLP1R (0.52) | GLP1RALDH1A1MMP2MMP9MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150150998-A1 | METHODS FOR OXIME CONJUGATION TO KETONE-MODIFIED POLYPEPTIDES | NOVARTIS AG (CH) | 2015-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150150998-A1 | METHODS FOR OXIME CONJUGATION TO KETONE-MODIFIED POLYPEPTIDES | PTMS, CRYAA, KRTCAP2 | GLP1R 1300/4885ALDH1A1 1155/4885MMP2 3444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.